Delivery Order SPE2DB25D3402-SPE2DB25FUGJF
- Not listed
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $6,391.17 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on June 26, 2025, with completion scheduled for June 27, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The company, headquartered in Conshohocken, Pennsylvania, serves as a major...
- The Defense Logistics Agency awarded a $9,263.85 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with an ultimate completion date of July 15, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.99 million...
- The Defense Logistics Agency awarded a $13,125.80 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pen injectors on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $16,045.54 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 28, 2025, with an ultimate completion date of August 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $55,018.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on June 18, 2025, with completion targeted for June 20, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $48,351.90 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 30, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $17,474.93 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 15, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various allergic and inflammatory conditions, including...
- SPE2DB25D3402Indefinite Delivery Contract
- SPE2DB25D3402-SPE2DB25FUGJFDelivery Order
The Defense Logistics Agency awarded a $15,470.70 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a specialty biologic medication used to treat conditions including atopic dermatitis, asthma, and eosinophilic esophagitis, making this delivery order part of DLA's broader pharmaceutical supply chain supporting military and federal healthcare systems. AmerisourceBergen, a major pharmaceutical distributor and critical federal healthcare vendor, has demonstrated extensive capability in fulfilling Defense Department medical procurement requirements across multiple therapeutic domains. The SPE2DX prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.5k | 7/18/25 |